Menu
Search
|

Menu

Close
X

Catabasis Pharmaceuticals Inc CATB.OQ (NASDAQ Stock Exchange Global Market)

0.75 USD
-- (--)
As of Jul 21
chart
Previous Close 0.75
Open --
Volume --
3m Avg Volume 114,428
Today’s High --
Today’s Low --
52 Week High 3.78
52 Week Low 0.74
Shares Outstanding (mil) 22.48
Market Capitalization (mil) 55.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.288
FY17
-1.280
FY16
-2.241
FY15
-2.176
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
2.60
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
19.07
16.84
LT Debt to Equity (MRQ)
vs sector
3.86
12.51
Return on Investment (TTM)
vs sector
-107.14
14.61
Return on Equity (TTM)
vs sector
-117.90
16.34

EXECUTIVE LEADERSHIP

Kenneth Bate
Co-Chairman of the Board, Since 2016
Salary: --
Bonus: --
Michael Ross
Director, Co-Chairman of the Board of Directors, Since 2016
Salary: --
Bonus: --
Jill Milne
President, Chief Executive Officer, Co-Founder, Director, Since 2016
Salary: $453,200.00
Bonus: $163,152.00
Deirdre Cunnane
Senior Vice President, General Counsel, Treasurer, Since 2016
Salary: --
Bonus: --
Andrew Nichols
Chief Scientific Officer, Since 2016
Salary: $316,750.00
Bonus: $118,627.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Kendall Sq Ste B14202
CAMBRIDGE   MA   02139-1573

Phone: +1617.3491971

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

SPONSORED STORIES